TrialBMC cancer2018

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5.

Robert Olson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.